Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Eye Infections, Bacterial | 8 | 2016 | 129 | 0.990 |
Why?
|
| Fear | 4 | 2024 | 60 | 0.990 |
Why?
|
| Endophthalmitis | 8 | 2016 | 122 | 0.860 |
Why?
|
| Colon | 3 | 2012 | 123 | 0.480 |
Why?
|
| Klebsiella Infections | 2 | 2012 | 12 | 0.380 |
Why?
|
| Bacillus cereus | 2 | 2011 | 59 | 0.350 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2011 | 91 | 0.350 |
Why?
|
| Enteric Nervous System | 1 | 2010 | 10 | 0.340 |
Why?
|
| Klebsiella pneumoniae | 3 | 2016 | 29 | 0.340 |
Why?
|
| Aminopyridines | 1 | 2010 | 8 | 0.340 |
Why?
|
| Constipation | 1 | 2010 | 22 | 0.340 |
Why?
|
| TRPV Cation Channels | 1 | 2010 | 16 | 0.330 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2010 | 32 | 0.330 |
Why?
|
| Piperazines | 1 | 2010 | 50 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 3 | 2011 | 536 | 0.310 |
Why?
|
| Glucocorticoids | 1 | 2008 | 115 | 0.270 |
Why?
|
| Mental Health | 2 | 2024 | 111 | 0.250 |
Why?
|
| Blood-Retinal Barrier | 2 | 2016 | 27 | 0.240 |
Why?
|
| Health Personnel | 1 | 2024 | 96 | 0.210 |
Why?
|
| Disease Models, Animal | 6 | 2015 | 1507 | 0.200 |
Why?
|
| Pharmacists | 1 | 2024 | 74 | 0.200 |
Why?
|
| Anxiety | 1 | 2024 | 158 | 0.200 |
Why?
|
| Aging | 1 | 2010 | 1016 | 0.200 |
Why?
|
| Pandemics | 1 | 2024 | 199 | 0.190 |
Why?
|
| Students, Pharmacy | 1 | 2024 | 90 | 0.190 |
Why?
|
| Male | 9 | 2024 | 13921 | 0.190 |
Why?
|
| Depression | 1 | 2024 | 225 | 0.190 |
Why?
|
| Smokers | 1 | 2023 | 128 | 0.180 |
Why?
|
| Diabetic Retinopathy | 3 | 2016 | 112 | 0.180 |
Why?
|
| Animals | 10 | 2016 | 10684 | 0.170 |
Why?
|
| Students, Medical | 1 | 2022 | 102 | 0.170 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 997 | 0.170 |
Why?
|
| Staphylococcus aureus | 3 | 2016 | 121 | 0.160 |
Why?
|
| Fluoroquinolones | 2 | 2009 | 15 | 0.150 |
Why?
|
| Humans | 9 | 2024 | 28851 | 0.130 |
Why?
|
| Retina | 3 | 2011 | 445 | 0.130 |
Why?
|
| Retinal Vessels | 2 | 2016 | 75 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 5 | 2016 | 1653 | 0.120 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2016 | 99 | 0.110 |
Why?
|
| Electroretinography | 3 | 2012 | 180 | 0.110 |
Why?
|
| Adult | 2 | 2024 | 8024 | 0.110 |
Why?
|
| Staphylococcal Infections | 1 | 2015 | 87 | 0.110 |
Why?
|
| Middle Aged | 1 | 2024 | 7414 | 0.100 |
Why?
|
| Female | 3 | 2024 | 15624 | 0.100 |
Why?
|
| Septal Nuclei | 1 | 2012 | 6 | 0.090 |
Why?
|
| Hyperalgesia | 1 | 2012 | 16 | 0.090 |
Why?
|
| Vitreous Body | 2 | 2011 | 23 | 0.090 |
Why?
|
| Pain Perception | 1 | 2012 | 17 | 0.090 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2012 | 98 | 0.090 |
Why?
|
| Vancomycin | 2 | 2011 | 59 | 0.090 |
Why?
|
| Vitrectomy | 1 | 2011 | 8 | 0.090 |
Why?
|
| Rabbits | 2 | 2011 | 277 | 0.090 |
Why?
|
| Mice | 5 | 2016 | 4802 | 0.090 |
Why?
|
| Submucous Plexus | 1 | 2010 | 1 | 0.090 |
Why?
|
| Interstitial Cells of Cajal | 1 | 2010 | 1 | 0.090 |
Why?
|
| Gastrointestinal Transit | 1 | 2010 | 8 | 0.090 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2010 | 14 | 0.080 |
Why?
|
| Cell Count | 1 | 2010 | 86 | 0.080 |
Why?
|
| Acetic Acid | 1 | 2010 | 28 | 0.080 |
Why?
|
| Rats | 2 | 2012 | 1588 | 0.080 |
Why?
|
| Rats, Wistar | 1 | 2010 | 153 | 0.080 |
Why?
|
| Models, Animal | 1 | 2010 | 130 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2010 | 190 | 0.080 |
Why?
|
| Ophthalmic Solutions | 1 | 2009 | 27 | 0.080 |
Why?
|
| Aza Compounds | 1 | 2009 | 11 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 612 | 0.070 |
Why?
|
| Quinolines | 1 | 2009 | 35 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 995 | 0.070 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2008 | 23 | 0.070 |
Why?
|
| Viscosity | 1 | 2008 | 40 | 0.070 |
Why?
|
| Neurons | 1 | 2010 | 297 | 0.070 |
Why?
|
| Biological Availability | 1 | 2008 | 44 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 78 | 0.070 |
Why?
|
| Virulence | 1 | 2008 | 153 | 0.070 |
Why?
|
| Receptor, Insulin | 1 | 2008 | 93 | 0.070 |
Why?
|
| Dexamethasone | 1 | 2008 | 63 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2008 | 149 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 209 | 0.070 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2007 | 24 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 465 | 0.060 |
Why?
|
| Social Workers | 1 | 2024 | 5 | 0.050 |
Why?
|
| Bacteria | 1 | 2007 | 286 | 0.050 |
Why?
|
| Aftercare | 1 | 2024 | 33 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2024 | 67 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2024 | 109 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2022 | 173 | 0.040 |
Why?
|
| Health Promotion | 1 | 2023 | 179 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 76 | 0.040 |
Why?
|
| Emotions | 1 | 2022 | 137 | 0.040 |
Why?
|
| Evans Blue | 1 | 2016 | 7 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2016 | 17 | 0.030 |
Why?
|
| Iodates | 1 | 2016 | 11 | 0.030 |
Why?
|
| Dextrans | 1 | 2016 | 23 | 0.030 |
Why?
|
| Angiography | 1 | 2016 | 35 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2016 | 37 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 465 | 0.030 |
Why?
|
| United States | 1 | 2021 | 2222 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 419 | 0.030 |
Why?
|
| Child | 1 | 2021 | 2287 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2016 | 1022 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2012 | 56 | 0.020 |
Why?
|
| Corticosterone | 1 | 2012 | 35 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2012 | 174 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2011 | 13 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2011 | 25 | 0.020 |
Why?
|
| Amygdala | 1 | 2012 | 52 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2012 | 172 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 303 | 0.020 |
Why?
|
| Neutrophils | 1 | 2011 | 183 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 1032 | 0.020 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2009 | 4 | 0.020 |
Why?
|
| Benzalkonium Compounds | 1 | 2009 | 9 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 2009 | 6 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 29 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 58 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2009 | 82 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2009 | 44 | 0.020 |
Why?
|
| Keratitis | 1 | 2009 | 31 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 66 | 0.020 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 67 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2008 | 169 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 233 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 585 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 515 | 0.020 |
Why?
|
| Morbidity | 1 | 2007 | 60 | 0.020 |
Why?
|
| Blindness | 1 | 2007 | 34 | 0.020 |
Why?
|
| Global Health | 1 | 2007 | 54 | 0.020 |
Why?
|
| Liver | 1 | 2008 | 471 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 2426 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 1613 | 0.010 |
Why?
|
| Prognosis | 1 | 2007 | 811 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2009 | 634 | 0.010 |
Why?
|